12:30 – 1:30pm, Foege N130A (Wallace H. Coulter Seminar Room)
Our laboratories have led the development of long-acting nanoformulated antiretroviral therapies (nanoART) to improve drug delivery and therapeutic outcomes for human immunodeficiency virus (HIV)-infected people. Understanding the interplay between HIV disease and ART can simplify drug regimens and improve disease outcomes. Interdisciplinary bioimaging, behavior, and nanopharmaceutics are used to evaluate virus, drug, immune, and age-related toxicities. ART pharmacokinetic, pharmacodynamics, drug-drug interactions measurement employ PXR humanization (the androstane receptor with replacement of the mouse Cyp3a with human CYP3A4). We developed a tool to improve ART delivery to viral reservoirs and called theranostics (simultaneous diagnostics and therapeutics). We used such approaches to facilitate the development of the next generation of viral-reservoir targeted antiviral therapies. The technique of flash nanoprecipitation and emulsion-sonication were used to package ART and magnetite generating particles of narrow size distributions, colloidal stability, and transverse relaxivities. These ultra-small superparamagnetic iron oxide encased into hydrophobic polymer cores. The combined delivery of drug using diagnostic magnetite make theranostics. Our testing platform also seeks to develop a humanized mouse brain. In the model HIV-1 replication, innate immune activation and antiretroviral responses are seen and can be linked to metabolic and neural impairments. We used these neuroAIDS models to study the consequences of the viral infection, as well and to develop novel treatment strategies that could serve to eradicate HIV-1 brain reservoirs
Dr. Howard E. Gendelman is the Margaret R. Larson Professor of Internal Medicine and Infectious Diseases, Chairman of the Department of Pharmacology and Experimental Neuroscience, and Director of the Center for Neurodegenerative Disorders at the University of Nebraska Medical Center. Dr. Gendelman is credited in unraveling how functional alterations in brain immunity induce metabolic changes and ultimately lead to neural cell damage for a broad range of infectious, metabolic and neurodegenerative disorders. These discoveries have had broad implications in developmental therapeutics aimed at preventing, slowing or reversing neural maladies. He is also credited for the demonstration that AIDS dementia is a reversible metabolic encephalopathy; a finding realized at the University of Nebraska Medical Center. His work has led to novel immunotherapy and nanomedicine strategies for Parkinson’s and viral diseases currently being tested in early clinical trials as a result of intense translational investigations. Dr. Gendelman obtained a Bachelor’s degree in Natural Sciences and Russian Studies with honors from Muhlenberg College and his M.D. from the Pennsylvania State University-Hershey Medical Center where he was the 1999 Distinguished Alumnus. He completed a residency in Internal medicine at Montefiore Hospital, Albert Einstein College of Medicine and was a Clinical and Research Fellow in Neurology and Infectious Diseases at the Johns Hopkins University Medical Center. He occupied senior faculty and research positions at the Johns Hopkins Medical Institutions, the National Institute of Allergy and Infectious Diseases, the Uniformed Services University of the Health Sciences Center, the Walter Reed Army Institute of Research, and the Henry Jackson Foundation for the Advancement in Military Medicine before joining the University of Nebraska Medical Center faculty in March of 1993. He retired from the US Army with the rank of Lieutenant Colonel. Dr. Gendelman has authored over 400 peer-reviewed publications, edited nine books and monographs, holds eight patents, is the Editor-In-Chief and Founder of the Journal of Neuroimmune Pharmacology along with service on numerous editorial boards, national and international scientific review and federal and state committees. He has been an invited lecturer to more than 200 scientific seminars and symposia and the recipient of numerous local, national and international honors. These, include, but are not limited to, the Henry L. Moses Award in Basic Science; the Carter-Wallace Fellow for Distinction in AIDS Research, the David T. Purtilo Distinguished Chair of Pathology and Microbiology, the UNMC Scientist Laureate; NU Outstanding Research and Creativity and the Joseph Wybran Distinguished Scientist Awards. Dr. Gendelman was named a J. William Fulbright Research Scholar at the Weizmann Institute of Science in Israel. In 2001, he received the prestigious Jacob Javits Neuroscience Research Award and the Career Research Award in Medicine from UNMC. He is included amongst a selective scientific group listed on highly cited.com as one of the top cited scientists in his field. Dr. Gendelman has trained more than forty scientists (students and postdoctoral fellows) who have themselves developed independent successful careers. Under his leadership, the department now holds scores of independent R01s or equivalent grants, four program project grants, and shares two program developmental awards. His leadership is credited with the growth of the Department of Pharmacology and Experimental Neuroscience at the University of Nebraska Medical Center to be amongst the top-like ranked and federally funded departments (top ten) nationwide; a particularly noted feat as its position was 77 when he assumed its leadership.